- Home
- PFO vs MCRB Comparison
PFO vs MCRB Comparison
Compare PFO & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PFO
- MCRB
- Stock Information
- Founded
- PFO 1991
- MCRB 2010
- Country
- PFO United States
- MCRB United States
- Employees
- PFO N/A
- MCRB N/A
- Industry
- PFO Finance Companies
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- PFO Finance
- MCRB Health Care
- Exchange
- PFO Nasdaq
- MCRB Nasdaq
- Market Cap
- PFO 121.4M
- MCRB 144.6M
- IPO Year
- PFO N/A
- MCRB 2015
- Fundamental
- Price
- PFO $9.73
- MCRB $20.69
- Analyst Decision
- PFO
- MCRB Hold
- Analyst Count
- PFO 0
- MCRB 4
- Target Price
- PFO N/A
- MCRB $14.33
- AVG Volume (30 Days)
- PFO 31.8K
- MCRB 227.9K
- Earning Date
- PFO 01-01-0001
- MCRB 11-12-2025
- Dividend Yield
- PFO 6.51%
- MCRB N/A
- EPS Growth
- PFO N/A
- MCRB N/A
- EPS
- PFO N/A
- MCRB 10.22
- Revenue
- PFO N/A
- MCRB N/A
- Revenue This Year
- PFO N/A
- MCRB N/A
- Revenue Next Year
- PFO N/A
- MCRB N/A
- P/E Ratio
- PFO N/A
- MCRB $2.05
- Revenue Growth
- PFO N/A
- MCRB N/A
- 52 Week Low
- PFO $6.90
- MCRB $6.53
- 52 Week High
- PFO $8.51
- MCRB $24.67
- Technical
- Relative Strength Index (RSI)
- PFO 65.78
- MCRB 59.63
- Support Level
- PFO $9.73
- MCRB $19.14
- Resistance Level
- PFO $9.90
- MCRB $21.97
- Average True Range (ATR)
- PFO 0.08
- MCRB 1.52
- MACD
- PFO -0.01
- MCRB 0.22
- Stochastic Oscillator
- PFO 45.89
- MCRB 79.06
About PFO Flaherty & Crumrine Preferred and Income Opportunity Fund Incorporated
Flaherty & Crumrine Prfd Income Oppo is the United States-based diversified, closed-end management investment company. Its primary investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.